Learn about the legal implications of new anti-discrimination protections for employees who consume cannabis, the use of "impairment expert" roles, and how employers can continue to enforce drug-free workplace policies while not violating cannabis use nondiscrimination laws.
Distinguished labor law practitioners will lead a lively discussion of the key labor law concepts and issues every cannabis lawyer should understand, from the National Labor Relations Act to Labor Peace Agreements.
As cannabis is incorporated in healthcare, providers and patients face new legal challenges in everything from licensing, payors, and accreditation hurdles, to DEA registrations, controlled-substance prescribing rules, fraud, right-to-try laws, and FDA oversight. With anticipation of rescheduling of cannabis to Schedule III substance, there will be a discussion on how it impacts healthcare delivery, patient access and provider liability issues.
The relatively sudden legalization of commercial cannabis has led attorneys to take on multiple roles for clients: brokers, business consultants, legal counselors, and more. Learn to identify ethical pitfalls in taking multiple jobs for a client - and when you must decline.
Designed to counter drug trafficking, money laundering, and other financial crimes, the Corporate Transparency Act poses particular challenges for the cannabis industry, such as fully disclosing beneficial owners in an industry still prohibited under federal law.
How should clients in the cannabis space expand into new markets? Here, industry lawyers will share their expertise in navigating IP licensing, partnerships, joint ventures, and more. Learn which strategies can accelerate your clients’ growth and which could pose risks.
Lawsuits around the country based on a constitutional principle referred to as the "dormant Commerce Clause" have upended the cannabis industry over the past two years. We will discuss the merits of these cases and how they may impact the shape and trajectory of the industry.
Recent developments have convinced many that the DEA will seek to transfer cannabis to schedule III of the Controlled Substances Act soon. Yet the mechanics of the administrative process and the implications of the proposed change are not well understood. Our panel will discuss the role of other federal agencies in the scheduling review process, the legal implications of cannabis’s scheduling status under federal law, and the implications rescheduling would have for state-regulated cannabis markets, FDA enforcement, and more.
A discussion of the how rescheduling, the potential end of 280E, and the SAFER Banking Act will impact the currently moribund cannabis financing and mergers and acquisitions.